Successful Treatment of Recalcitrant Palmoplantar Psoriasis with Etanercept

Cutis

Volumn 72, Issue 5, 2003, Pages 396-398

  Weinberg, Jeffrey M ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIPOTRIOL; COAL TAR; DERMATOLOGICAL AGENT; ETANERCEPT; HYBRID PROTEIN; HYDROXYZINE; IMMUNOGLOBULIN G; PSORALEN; STEROID; TAZAROTENE; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; ULOBETASOL PROPIONATE;

ADULT; ARTHRITIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DRUG ADMINISTRATION; DRUG EFFICACY; ERYTHEMA; FEMALE; HAND DISEASE; HUMAN; INTRADERMAL DRUG ADMINISTRATION; PATHOLOGY; PHOTOTOXICITY; PSORIASIS; PUSTULOSIS PALMOPLANTARIS; PUVA; RECURRENT DISEASE; SKIN DISEASE; STEROID THERAPY; TOPICAL TREATMENT; TREATMENT FAILURE; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; DERMATOLOGIC AGENTS; DIAGNOSIS, DIFFERENTIAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; RECURRENCE;

EID: 0346218045     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Marsland AM, Griffiths CE. Treatments for chronic palmoplantar pustular psoriasis. Skin Therapy Lett. 2001;6:3-5.
2. Lassus A, Geiger JM. Acitretin and etretinate in the treatment of palmoplantar pustulosis: a double-blind comparative trial. Br J Dermatol. 1988;119:755-759.
3. Layton AM, Sheehan-Dare R, Cunliffe WJ. A double-blind, placebo-controlled trial of topical PUVA in persistent palmoplantar pustulosis. Br J Dermatol. 1991;124:581-584.
4. Matsunami E, Takashima A, Mizuno N, et al. Topical PUVA, etretinate, and combined PUVA and etretinate for palmoplantar pustulosis: comparison of therapeutic efficacy and the influences of tonsillar and dental focal infections. J Dermatol. 1990;17:92-96.
5. Weinberg JM, Saini R. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept. Cutis. 2003;71:25-29.
6. Gottlieb AB, Matheson R, Lowe NJ, et al. Efficacy of Enbrel in patients with psoriasis [abstract]. J Invest Dermatol. 2002;119:234.
7. Iyer S, Yamauchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol. 2002;146:118-121.
8. Kamarashev J, Lor P, Forster A, et al. Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept. Dermatology. 2002;205:213-216.
9. Leonardi C, Gottlieb AB, Zitnik R. Efficacy and safety of Enbrel (etanercept) in patients with psoriasis: results of a phase 3 study. Poster presented at: International Investigative Dermatology 2003; April 30-May 4, 2003; Miami Beach, Fla. Poster 0409.